



## Magenta Therapeutics Appoints David Nichols as Chief Technical Officer

April 19, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 19, 2021-- [Magenta Therapeutics](#) (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of David Nichols as Chief Technical Officer.

"We are so pleased to welcome David to Magenta as an experienced CMC and manufacturing executive with a strong track record of leadership and expertise," said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. "I look forward to working closely with David as Magenta progresses our preclinical and clinical programs to the next stage."

As Chief Technical Officer, Mr. Nichols will serve as a member of the Company's Executive Team and will lead all of Magenta's CMC activities from early development through commercial products across the company's pipeline, including driving strategic initiatives to improve efficiency, consistency, compliance and risk mitigation for Magenta's antibody drug conjugate, cell therapy, and peptide manufacturing processes.

Mr. Nichols comes to Magenta with more than 25 years of experience in biologics process development across the life sciences industry. Most recently, Mr. Nichols served as Senior Vice President of Kiniksa Pharmaceuticals, Ltd., where he was responsible for all process development and internal and external GMP manufacturing. Previously, he served as Head of CMC Biologicals Drug Substances at Tesaro Pharmaceuticals; Senior Director of Process Development at Operations at Teva Pharmaceuticals; Senior Director, CMC Integration at Shire Pharmaceuticals, among other titles of increasing responsibilities at the organization.

Mr. Nichols holds an MBA from Northeastern University and a Masters in Biochemistry from the University of New Hampshire.

### About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit [www.magentatx.com](http://www.magentatx.com).

Follow Magenta on Twitter: @magentatx.

### Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption "Risk Factors" in Magenta's Annual Report on Form 10-K filed on March 3, 2021, as updated by Magenta's most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210419005067/en/): <https://www.businesswire.com/news/home/20210419005067/en/>

Magenta Therapeutics:  
Lyndsey Scull, Director, Corporate Communications, Magenta Therapeutics  
202-213-7086  
[lscull@magentatx.com](mailto:lscull@magentatx.com)

Investor inquiries:  
Jill Bertotti, W2O Group  
714-225-6726  
[jbortotti@w2ogroup.com](mailto:jbortotti@w2ogroup.com)

Media inquiries:  
Dan Budwick  
1AB  
[dan@1abmedia.com](mailto:dan@1abmedia.com)

